# US 2006/0078621 A1 · Method of providing customized drug delivery systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078621 A1
- Document ID: US20060078621A1
- Status: Published application
- Kind: A1
- Application number: 10/964,127
- Filed: 2004-10-13
- Published: 2006-04-13
- Earliest claimed: 2004-10-13
- Inventors: Robert Wedinger; Dev Mehra; Wendy Wilson
- Web page: https://patentgrep.com/patent/US20060078621A1

## CPC

- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel method of correlating the disposition of a specific drug in an individual patient to a controlled and modulated delivery system for optimizing therapeutic response of orally ingested dosage forms is provided. Such a method broadly encompasses a first determination of an individual's metabolic rate in terms of absorption of pharmaceutical materials from within the gastrointestinal tract measured as blood plasma concentration over a specific period of time after ingestion or by other commercially available methods and subsequent determination: 1) predicting a proper pharmaceutical compositions, in terms of amount of active available for absorption by the target patient; and 2) amount of such active pharmaceutical ingredient (API) to be formulated within a drug-delivery device that will take into account the unique metabolic profile of the drug (or drugs) in a specific patient. As a result, the API may be formulated as beads, pellets, minitablets, powders, granules, suspensions, and/or emulsions present within the drug-delivery source. As one potentially preferred embodiment, such beads and/or pellets, which may be coated with different polymers and differing levels of coatings, are selected in response to the initial determination of the patient's metabolic profile in order to ensure the specific targeted patient receives the most efficient dosage of the active drug at a rate unique to that individual.

## Claims

### Claim 1

A method of producing a drug delivery system comprised of a plurality of active pharmaceutical ingredient (API)-containing materials selected from the group consisting of beads, pellets, minitablets, emulsions, suspensions, powders, and any mixtures thereof;
said method comprising dispensing said API-containing materials into said drug delivery system from a plurality of different bins;
wherein each individual bin comprises a uniform API-containing material and each separate bin comprises different API-containing materials having different dosages and formulations as those materials present within different bins;
wherein the total amount of each different API-containing material from at least two of the plurality of different bins selected for inclusion within said drug delivery system is determined through the correlation of a specific patient's metabolic profile for the API present within said API-containing materials;
wherein the selected numbers of different materials from the different bins are then introduced within a drug delivery system; and
wherein the final formulation present within said drug delivery system is customized to the metabolic profile of said specific patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein said API-containing materials are selected from the group consisting of beads, pellets, minitablets, and any mixtures thereof.

### Claim 3 (depends on 1)

A drug delivery system produced by the method of claim 1.

### Claim 4 (depends on 2)

A drug delivery system produced by the method of claim 2.

### Claim 5 (depends on 3)

The drug delivery system of claim 3 wherein said system is selected from the group consisting of a capsule, a tablet, and mixtures thereof.

### Claim 6 (depends on 4)

The drug delivery system of claim 4 wherein said system is selected from the group consisting of a capsule, a tablet, and mixtures thereof.
